76 results
8-K
EX-99.1
REPL
Replimune Group Inc
8 Jan 24
Regulation FD Disclosure
8:00am
doubling of the CR rate for RP1+cemiplimab vs cemiplimab alone (48.1% vs 22.6%) CRs are the key driver of long-term clinical benefit in CSCC BOR (confirmed
S-3ASR
REPL
Replimune Group Inc
3 Aug 23
Automatic shelf registration
8:45am
or regulated investment companies;
certain former citizens or long-term residents of the U.S.;
persons who hold our Common Stock as part
S-3ASR
EX-1.2
58w6aq0b pkwcb46
3 Aug 23
Automatic shelf registration
8:45am
8-K
EX-1.1
hugz8
12 Dec 22
Replimune Announces Proposed Public Offering
5:00pm
424B5
93n379j
12 Dec 22
Prospectus supplement for primary offering
6:03am
424B5
vj8teg2
7 Dec 22
Prospectus supplement for primary offering
4:58pm
8-K
EX-99.1
c3wj7ud67uh9q63d
7 Oct 22
Entry into a Material Definitive Agreement
8:20am